Retatrutide (LY-3437943) is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors, three pathways that regulate appetite, metabolism, and fat oxidation
Common adverse effects of Ozempic, as documented in the UK SmPC, include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, abdominal pain (very common, affecting more than 1 in 10 patients) Decreased appetite (very common) Hypoglycaemia : when used in combination with insulin or sulphonylureas Gallbladder disorders : including cholelithiasis and cholecystitis Fatigue Injection site reactions : such as bruising or pain Whilst musculoskeletal pain is not formally listed, healthcare professionals should remain vigilant for patient reports and consider the broader context of treatment, including weight loss trajectory, nutritional status, and concurrent medical conditions
Pricing and availability may change
[DOI] [PubMed] [Google Scholar] 78.Amiot M., Riva C., Vinet A
As of now, no drugmaker has an early-stage migraine-specific GLP-1 drug program, according to publicly available information
The markets development in the region is highly propelled by an expansion in healthcare expenditure, an increase in the acceptance of GLP-1 receptor, a rise in obesity and diabetes prevalence, a surge in the demand for effective glycemic control therapies, and improved accessibility to generic and branded formulations
